Semenchenko et al. conducted a preliminary evaluation of the effect of XRP44X on the tumor in three preclinical mouse models and found that XRP44X inhibits tumor growth and metastasis through mechanisms involving Elk3. This evidence concerns the gene ELK3 and neoplasm.